


Dear John Doe,

Please find the Ignite RPPA Breast Assay report for Jane Doe.

We greatly appreciate your support and look forward to working with you again.

Sincerely,



Carlyne D. Cool, M.D.
Medical Director
Ignite Proteomics

Patient	Specimen	Timeline
Date of Birth: 01/01/1901 Sex: Female MRN: 1234567 Theralink ID: TT23-00101	Specimen ID: AB00-12345-67 Specimen Type: Biopsy Collection Site: Liver	Specimen Collected: 01/01/1901 Test Ordered: 11/02/2023 Specimen Received: 11/20/2023

Provider
John Doe - Test Cancer Center 1234 Test Center Road, Suite 1111, Warrenton, VA 20187, Phone: 123-456-7890

Diagnosis and Treatment History	
Diagnosis: Metastatic breast cancer Stage: Stage III Histology: Metastatic carcinoma, with morphologic and immunophenotypic features consistent with mammary origin	Line of Therapy: Faslodex-Everolimus, Tamoxifen+Goserelin (2018), Letrozole, Palbociclib,Goserelin (2021)

Hormonal Status
ER: Positive 94%, 2+ PR: Positive 83%, 1+ HER2: Negative (IHC 1+)

On-Label Options

AKT kinase inhibitor, such as capivasertib

AKT S473

AKT T308

PI3K inhibitor, such as alpelisib

AKT S473

AKT T308

Off-Label Options

anti-PD1 agent, such as pembrolizumab

PDL1

antiandrogens

AR

EGFR kinase inhibitor, such as erlotinib, gefitinib


EGFR Y1068

HER2 Y1248

Shc Y317

high EGFR activation together with low HER2 activation indicates sensitivity to EGFR-specific kinase inhibitors over EGFR/HER2 kinase inhibitors

Complete Assay Results



The Ignite RPPA Assay utilizes a Reverse Phase Protein Array (RPPA) panel test to quantify the expression of proteins and phosphoproteins. Individual biomarkers are reported as a percentage, scaled to a reference population of primary breast tumor samples. Values preceded by ">" exceed the highest calibrated point for this analyte and array and are capped.

Method: The Ignite RPPA Assay utilizes a Reverse Phase Protein Array (RPPA) methodology to quantify the expression of proteins and phosphoproteins. Individual biomarkers are reported as a percentage, scaled to the Ignite Proteomics reference population of primary breast tumor samples. Assay limits of sensitivity for total protein input are ≥ 100 ug/ml and ≤ 400 ug/ml. Limits of sensitivity for individual analytes don't apply due to reporting as percentage.

